Startups channel feed – Endpoints News

Startups channel feed

A transpacific biotech startup combines Asian investors and some seriously trendy science out of MIT

8 years ago

Cancer drug to treat dwarfism? Abandoned Novartis asset snagged by BridgeBio’s QED Therapeutics

8 years ago

Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D

8 years ago

Ex-Merrimack CEO Mulroy launches oncology startup Partner Therapeutics

8 years ago

The new serial entrepreneur in the biotech arena launches another upstart looking to drug RNA

8 years ago

When VCs hand out mega-rounds to Vir and Gossamer, are they betting on the jockey or the horse?

8 years ago

Allied with Penn, Tmunity’s cell therapy pioneers bag $100M mega-round to back a breakthrough quest on CAR-T, CRISPR

8 years ago

With $58M in hand, the startup team at Pandion sets their sights on a next-gen approach to immunology

8 years ago

Google backs $27M launch round for Holy Grail R&D work on two targets: a cancer vaccine and a universal flu jab

8 years ago

Jumping on anti-aging bandwagon, Y Combinator joins hunt for the $100B pill

8 years ago

The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds

8 years ago

Pfizer inks deal with startup Adapsyn to search microbes for novel compounds

8 years ago

Faheem Hasnain and his ex-Receptos team launch a new biotech with $100M and a twist on the old biotech model

8 years ago

Atlas builds its dream team and hands over $25M to launch a new approach to gene therapy

8 years ago

What break? Sarepta vet Ed Kaye quickly pivots to the helm of another biotech upstart with a $40M bankroll

8 years ago

Upstart Expansion bags a $55M launch round to join the hunt for RNA-targeting small molecules

8 years ago

Ex-Pfizer CEO's startup Centrexion gets $67M for PhIII painkiller

8 years ago

Google backs a $60M transition round for FLX’s switch to a CCR4 strategy

8 years ago

In gene therapy's second big win this week, Orchard nabs $110M Series B

8 years ago

Flagship adds $618M in new funds to fuel startup mission

8 years ago

Jnana launches with $50M to spotlight an unexplored protein territory

8 years ago

Its underlying biology 'too complicated' for further investment, Atlas-seeded Raze signs off

8 years ago

Ex-Dezima CEO co-founds NASH startup, flying into Phase IIB with €25 million

8 years ago

Rich Heyman's Metacrine grabs a $22M round in search of a superior NASH drug

8 years ago

First page Previous page 65 66 676869 70 71 Next page Last page